GLP-1 Medications and the Dietitian's Role: What Happens After the Injection

GLP-1 receptor agonists, the class that includes semaglutide and tirzepatide, are the most significant pharmacological development in metabolic medicine in a generation. The clinical results are real. The weight loss is meaningful. The improvements in glycaemic control, cardiovascular risk markers, and in some cases hepatic steatosis are well-documented in the trial literature and increasingly visible in clinical practice.

They are also generating a second-order clinical problem that most prescribers are not addressing. The medication suppresses appetite. It does not teach a man how to eat. It changes the relationship with hunger. It does not change the underlying drivers of metabolic dysfunction. For the men we see at Miller Health who are taking or considering a GLP-1, the question is not whether the medication works. It is what to do with the time and the weight loss the medication creates.

What GLP-1 Medications Actually Do

GLP-1 is a naturally occurring hormone released by the gut in response to eating. It slows gastric emptying, suppresses appetite, enhances insulin secretion in response to glucose, and reduces glucagon release. Pharmaceutical GLP-1 receptor agonists mimic this effect at supraphysiological levels and over a much longer half-life, producing sustained appetite suppression and improved glycaemic control.

The result for most men taking them is a significant reduction in caloric intake, weight loss in the order of 15 to 20 percent of body weight over twelve to eighteen months in the better-responding population, and meaningful improvements across a range of metabolic markers.

That is the headline. The clinical detail is more interesting.

The Body Composition Question Nobody Is Asking

Weight loss on GLP-1 medications is not pure fat loss. Research published in JAMA Internal Medicine and the New England Journal of Medicine has shown that a substantial proportion of the weight lost on these medications is lean tissue, including skeletal muscle. Estimates vary across studies but figures of 25 to 40 percent of total weight lost being lean mass are reported in the higher end of analyses.

For a man in his forties or fifties who already has age-related sarcopenia in progress, losing significant lean mass through a pharmacologically driven caloric reduction is not a benign outcome. Muscle is the primary site of glucose disposal in the body. Lean mass is the principal determinant ofresting metabolic rate. Reduced muscle mass is associated with poorer physical function, lower testosterone, reduced metabolic flexibility, and a markedly worse cardiovascular and metabolic risk profile in the long term.

ADEXA scan before and during GLP-1 therapy quantifies what is happening to body composition with clinical precision. Without it, you are working blind. The number on the scale can be moving in the right direction while the underlying biology is being quietly compromised.

Protein, Resistance Training, and the Lean Mass Preservation Protocol

The clinical literature points clearly to the interventions that protect lean mass during pharmacologically driven weight loss. Adequate protein intake, specifically 1.6 to 2.2 grams per kilogram of body weight depending on activity level and goals, is the first foundation. Most men starting a GLP-1 are eating far less than this on the medication, often without noticing, because appetite suppression makes meeting any nutritional target more difficult.

Progressive resistance training is the second foundation. Heavy compound movements at sufficient volume and intensity to provide a hypertrophic stimulus are required. Walking is not enough. Pilates is not enough. Resistance loading creates the physiological demand that signals to the body to preserve and rebuild muscle tissue against a caloric deficit.

The third foundation is meal timing and nutrient density. With a smaller eating window driven by suppressed appetite, every meal needs to count. Calorically dense low-nutrient foods displace the protein, micronutrients, and fibre that a man on a GLP-1 needs more than ever.

These are not optional add-ons. They are the difference between a clinically excellent GLP-1 outcome and one that creates a worse metabolic foundation than the starting point.

The Nutrient Status Problem

Reduced food intake on GLP-1 therapy has clinical consequences beyond protein and caloric content. Micronutrient deficiencies become significantly more common. Vitamin D, vitamin B12, iron, magnesium, and zinc are all at elevated risk of falling into deficiency or insufficiency under sustained appetite suppression.

These deficiencies are not academic. Low vitamin D depresses testosterone, impairs immune function, and is associated with poor bone density. Low iron and ferritin drive fatigue and reduce cognitive performance. Low B12 causes neurological symptoms and exacerbates the cognitive complaints that often present alongside the metabolic ones.

At Miller Health, our advanced blood panel covers all of these markers. For a man on a GLP-1 medication, periodic monitoring of nutrient status is not optional. It is part of competent clinical management.

What Happens When the Medication Stops

GLP-1 medications work while you take them. The clinical trial data on cessation is consistent: appetite returns, weight is regained, and metabolic markers tend to revert toward baseline within twelve months of stopping. This pattern is not a failure of willpower. It is the pharmacological reality of the medication.

The men who maintain the gains they have made on a GLP-1 after stopping are those who have used the period of appetite suppression to establish sustainable habits, rebuilt lean muscle mass through resistance training, and developed an actual relationship with eating that is not dependent on the medication. That is dietitian-led work. It does not happen passively.

The Miller Health Approach to GLP-1 Support

We do not prescribe GLP-1 medications. We are not a TRT or weight loss clinic. We work alongside the physicians who do prescribe, providing the clinical nutrition support that determines whether the pharmacological intervention produces a good outcome or a compromised one.

For a man considering or already taking a GLP-1, the appropriate clinical starting point is theExplore assessment. DEXA scan to baseline body composition. Advanced blood panel to establish metabolic and nutrient status. Resting metabolic rate to anchor caloric targets. Clinical review with an HCPC-registered dietitian who can interpret all of it together and build a protein, resistance training, and nutrient strategy specific to your numbers.

TheEngage programme that follows provides twelve weeks of structured support to implement and adapt that protocol as your body composition changes. For men on a GLP-1, this is often the difference between losing weight and losing the right kind of weight.

When a GLP-1 Is Genuinely Appropriate

The clinical case for GLP-1 medications is strongest in men with significantly elevated visceral fat, established insulin resistance, type 2 diabetes, or class 2 or 3 obesity where conventional intervention has been attempted and has not produced sustained results. In those contexts, the medication is genuinely useful and the benefits frequently outweigh the costs.

The case is weaker, and the lean mass concerns more relevant, in men with moderate body fat who are seeking aesthetic or modest metabolic improvement and could achieve their goals through diet, training, and lifestyle intervention alone. For these men, the assessment we provide can sometimes clarify that the medication is not the right tool, and the same outcomes are achievable through clinical nutrition support without the pharmacological cost.

This is the conversation that does not happen in a fifteen-minute appointment with a private weight loss clinic. It is the conversation that happens at Miller Health.

Book Your Pre-GLP-1 or On-GLP-1 Assessment

If you are considering a GLP-1 medication, or already taking one, the Explore assessment provides the clinical baseline that determines whether the intervention is doing what you want it to. £1,950 at 25 Harley Street, London.